#Lineage-specific #pathogenicity, immune #evasion, and virological #features of #SARS-CoV-2 #BA286 / #JN1 and #EG51 / HK.3

Source: Nature Communications, AbstractSARS-CoV-2 JN.1 with an additional L455S mutation on spike when compared with its parental variant BA.2.86 has outcompeted all earlier variants to become the dominant circulating variant. Recent studies investigated the immune resistance of SARS-CoV-2 JN.1 but additional factors are speculated to contribute to…

https://etidioh.wordpress.com/2024/10/09/lineage-specific-pathogenicity-immune-evasion-and-virological-features-of-sars-cov-2-ba286-jn1-and-eg51-hk-3/

#Lineage-specific #pathogenicity, immune #evasion, and virological #features of #SARS-CoV-2 #BA286 / #JN1 and #EG51 / HK.3

Source: Nature Communications, AbstractSARS-CoV-2 JN.1 with an additional L455S mutation on spike when compared with its parental variant BA.2.86 has outcompeted all earlier variants to become the …

ETIDIoH

Immunogenicity and #efficacy of #XBB15 rS #vaccine against the #EG51 #variant of #SARS-CoV-2 in Syrian #hamsters, J Virol.: https://journals.asm.org/doi/full/10.1128/jvi.00528-24?af=R

Thus, based on these study results, the protein-based XBB.1.5 vaccine is immunogenic and increased the breadth of protection against the Omicron EG.5.1 variant in the Syrian hamster model.

Increased #pathogenicity {in animal models} and #transmission of #SarsCoV2 #Omicron #XBB19 #sublineage, including #HK3 and #EG51, BioRxIV, https://www.biorxiv.org/content/10.1101/2024.06.10.598324v1?rss=1

HK.3 and EG.5.1 exhibited greater pathogenicity than XBB.1.9.1 and BA.2 in H11-K18-hACE2 #hamsters. Our studies provide insight into the newly emerging #pathogens HK.3 and EG.5.1.

Evaluating #Humoral #Immunity Elicited by #XBB15 Monovalent #COVID19 #Vaccine, Emerg Infect Dis.: https://wwwnc.cdc.gov/eid/article/30/6/24-0051_article

We report boosting of #IgG (2.1×), #IgA (1.5×), and total IgG/A/M (1.7×) targeting the #spike receptor-binding domain and neutralizing titers against WA1 (2.2×), XBB.1.5 (7.4×), #EG51 (10.5×), and #JN1 (4.7×) variants.

Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine

Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine

Emerging Infectious Diseases journal

Virological characteristics of the #SARS-CoV-2 #BA286 #variant, Cell: https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(24)00005-2?rss=yes

• BA.2.86 is more transmissible than the currently predominant #EG51
• The sensitivity of BA.2.86 to #antiviral #drugs is comparable to that of EG.5.1
• The #replication efficiency of BA.2.86 in vitro and in vivo is lower than that of EG.5.1
• In hamsters, BA.2.86 is less #pathogenic than EG.5.1 and the parental BA.2

𝗟𝗔𝗧𝗘𝗦𝗧 𝗨𝗞 #COVID19

🧪𝗖𝗮𝘀𝗲𝘀 — weekly
🔻5,255

🧮𝗧𝗼𝗽 𝗩𝗮𝗿𝗶𝗮𝗻𝘁𝘀
#JN1 #HV1 #EG51

🏥𝗛𝗼𝘀𝗽𝗶𝘁𝗮𝗹 𝗔𝗱𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀 — weekly
🔺3,401

🕯️𝗗𝗲𝗮𝘁𝗵𝘀 — weekly
🔺388

🕯️𝗧𝗢𝗧𝗔𝗟 𝗗𝗲𝗮𝘁𝗵𝘀
🔺235,416

➡️http://PMP-Magazine.com/covid-19-today/

#COVIDisNotOver 😷

Latest COVID 🦠 TODAY’S DATA

Today’s COVID-19 data.

PMP Magazine

𝗟𝗔𝗧𝗘𝗦𝗧 𝗨𝗞 #COVID19

🧪𝗖𝗮𝘀𝗲𝘀 — weekly
🔻6,117

🧮𝗧𝗼𝗽 𝗩𝗮𝗿𝗶𝗮𝗻𝘁𝘀
#JN1 #HV1 #EG51

🏥𝗛𝗼𝘀𝗽𝗶𝘁𝗮𝗹 𝗔𝗱𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀 — weekly
🔻3,298

🕯️𝗗𝗲𝗮𝘁𝗵𝘀 — weekly
🔺301

🕯️𝗧𝗢𝗧𝗔𝗟 𝗗𝗲𝗮𝘁𝗵𝘀
🔺235,028

➡️http://PMP-Magazine.com/covid-19-today/

#COVIDisNotOver 😷

Latest COVID 🦠 TODAY’S DATA

Today’s COVID-19 data.

PMP Magazine
Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo - PubMed

EG.5.1 is a subvariant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB variant that is rapidly increasing in prevalence worldwide. However, the pathogenicity, transmissibility, and immune evasion properties of isolates of EG.5.1 are largely unknown. Here, we show that …

PubMed
''Omicron #XBB15 #vaccine on days 8–10 strongly + anti-S #IgG in all vaccinees & elicited potent neutralising responses vs previous & contemporary SARS-CoV-2 lineages, including #EG51 & #BA286. ... updated monovalent vaccine mRNA-1273.815 ... also increased nAbs titres against XBB sublineages in manufacturer preprint data. ...these data suggest that XBB.1.5-containing mRNA vax most likely increase protection vs COVID19 caused by currently circulating XBB subv. and emerging BA.2.86.''